Ascendis Pharma A (ASND) Net Cash Flow (2014 - 2026)

Ascendis Pharma A has reported Net Cash Flow for 13 years, with the latest figure at -$60.1 million in Q1 2026.

• Quarterly Net Cash Flow fell 72.83% year-over-year to -$60.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$113.3 million (down 153.56% YoY) and the FY2025 annual result came in at -$92.0 million, down 159.54% from the prior year.
• Net Cash Flow grew to -$60.1 million in Q1 2026 per ASND's latest filing, from -$95.8 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $407.7 million in Q3 2024 and troughed at -$144.0 million in Q4 2022.
• A 5-year average of -$2.7 million and a median of -$60.1 million in 2026 frame the typical range for Net Cash Flow.
• The widest YoY moves for Net Cash Flow: up 816.62% in 2024, down 222.3% in 2024.
• Over 5 years, Net Cash Flow stood at -$144.0 million in 2022, then jumped by 68.71% to -$45.1 million in 2023, then slumped by 107.43% to -$93.5 million in 2024, then fell by 2.46% to -$95.8 million in 2025, then surged by 37.27% to -$60.1 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$60.1 million, -$95.8 million, and $47.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.